IL290889A - Pyrrolopyrimidine compounds inhibit perk - Google Patents

Pyrrolopyrimidine compounds inhibit perk

Info

Publication number
IL290889A
IL290889A IL290889A IL29088922A IL290889A IL 290889 A IL290889 A IL 290889A IL 290889 A IL290889 A IL 290889A IL 29088922 A IL29088922 A IL 29088922A IL 290889 A IL290889 A IL 290889A
Authority
IL
Israel
Prior art keywords
pyrrolopyrimidine compounds
perk inhibiting
perk
inhibiting
pyrrolopyrimidine
Prior art date
Application number
IL290889A
Other languages
English (en)
Hebrew (he)
Original Assignee
Hibercell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hibercell Inc filed Critical Hibercell Inc
Publication of IL290889A publication Critical patent/IL290889A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL290889A 2019-08-29 2022-02-24 Pyrrolopyrimidine compounds inhibit perk IL290889A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962893528P 2019-08-29 2019-08-29
PCT/US2020/048621 WO2021041975A1 (en) 2019-08-29 2020-08-28 Perk inhibiting pyrrolopyrimidine compounds

Publications (1)

Publication Number Publication Date
IL290889A true IL290889A (en) 2022-04-01

Family

ID=72470610

Family Applications (1)

Application Number Title Priority Date Filing Date
IL290889A IL290889A (en) 2019-08-29 2022-02-24 Pyrrolopyrimidine compounds inhibit perk

Country Status (12)

Country Link
US (1) US20220356186A1 (https=)
EP (1) EP4021908A1 (https=)
JP (1) JP2022546414A (https=)
KR (1) KR20220066290A (https=)
CN (1) CN114710956A (https=)
AU (1) AU2020336975A1 (https=)
BR (1) BR112022003584A2 (https=)
CA (1) CA3152508A1 (https=)
IL (1) IL290889A (https=)
MX (1) MX2022002446A (https=)
PH (1) PH12022550491A1 (https=)
WO (1) WO2021041975A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114585606A (zh) 2019-08-29 2022-06-03 希伯塞尔股份有限公司 抑制perk的化合物
RS65962B1 (sr) 2020-05-08 2024-10-31 Halia Therapeutics Inc Inhibitori nek7 kinaze
CN117597346A (zh) * 2021-04-05 2024-02-23 哈利亚治疗公司 Nek7抑制剂
WO2022216680A1 (en) * 2021-04-05 2022-10-13 Halia Therapeutics, Inc. Nek7 inhibitors
US20240287081A1 (en) * 2021-06-09 2024-08-29 Icahn School Of Medicine At Mount Sinai Perfluoroalkane substituted pyrazolo[3,4-d]pyrimidin and pyrrolo[2,3-d]pyrimidin compounds and uses thereof
US20250000859A1 (en) 2021-08-25 2025-01-02 Alesta Therapeutics BV Use of gcn2 inhibitors in treating cancer
GB202407386D0 (en) 2024-05-24 2024-07-10 Apollo Ap45 Ltd 1H-pyrazolo(4,3-D)pyrimidine derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903297A (en) 1973-11-01 1975-09-02 Upjohn Co Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs
US7863444B2 (en) * 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
TR199902301T2 (xx) * 1997-03-19 1999-12-21 Basf Aktiengesellschaft Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
CA2794153C (en) 2010-03-25 2018-01-02 Glaxosmithkline Llc Substituted indoline derivatives as perk inhibitors
JP6493218B2 (ja) * 2013-11-08 2019-04-03 小野薬品工業株式会社 ピロロピリミジン誘導体
WO2016004254A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
WO2016085160A2 (ko) * 2014-11-28 2016-06-02 (주)네오팜 발모촉진용 또는 탈모방지용 조성물
GB201508747D0 (en) * 2015-05-21 2015-07-01 Univ Edinburgh Compounds
WO2017046739A1 (en) * 2015-09-15 2017-03-23 Glaxosmithkline Intellectual Property (No.2) Limited Imidazolidinone derivatives as inhibitors of perk
TW201722957A (zh) * 2015-09-15 2017-07-01 葛蘭素史克智慧財產(第二)有限公司 化學化合物
ES2965081T3 (es) * 2016-07-07 2024-04-11 Daewoong Pharmaceutical Co Ltd Derivados 4-aminopirazolo[3,4-d]pirimidinil-azabiciclo y composición farmacéutica que comprende dichos derivados
RS65914B1 (sr) * 2017-04-18 2024-10-31 Lilly Co Eli Fenil-2-hidroksi-acetilamino-2-metil-fenil jedinjenja

Also Published As

Publication number Publication date
US20220356186A1 (en) 2022-11-10
CN114710956A (zh) 2022-07-05
KR20220066290A (ko) 2022-05-24
PH12022550491A1 (en) 2023-02-06
EP4021908A1 (en) 2022-07-06
BR112022003584A2 (pt) 2022-05-24
MX2022002446A (es) 2022-06-02
JP2022546414A (ja) 2022-11-04
WO2021041975A1 (en) 2021-03-04
AU2020336975A1 (en) 2022-03-31
CA3152508A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
IL290889A (en) Pyrrolopyrimidine compounds inhibit perk
IL289463A (en) Agonist-gipr compounds
SG11202100525SA (en) Pyrrolopyrimidine itk inhibitors
LT3762368T (lt) Aminopirazindiolio junginiai, kaip pi3k-γ inhibitoriai
GB201905721D0 (en) Compounds
GB201914860D0 (en) Inhibitor compounds
IL290087A (en) inhibitory substances
IL279698A (en) Compounds that increase proteasome activity
GB201916915D0 (en) Compounds
GB201910305D0 (en) Compounds
GB201908536D0 (en) Compounds
GB201905328D0 (en) Inhibitor compounds
GB201910304D0 (en) Compounds
GB201908171D0 (en) Compounds
GB201908095D0 (en) Carboxy-MIDA-boronate compounds
HK40077027A (en) Perk inhibiting pyrrolopyrimidine compounds
HK40077026A (en) Perk inhibiting compounds
HK40055501A (en) Pyrrolopyrimidine itk inhibitors
GB201919205D0 (en) Compounds
GB201918761D0 (en) Compounds
GB201918424D0 (en) Compounds
GB201917891D0 (en) Compounds
GB201917895D0 (en) Compounds
GB201917893D0 (en) Compounds
GB201916847D0 (en) Compounds